Brokerages Set Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Target Price at $109.25

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) have earned an average recommendation of “Moderate Buy” from the nineteen research firms that are presently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating, thirteen have given a buy rating and three have assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $109.25.

A number of brokerages have recently commented on GPCR. BMO Capital Markets set a $145.00 price target on Structure Therapeutics and gave the company an “outperform” rating in a research note on Tuesday, March 17th. Wolfe Research began coverage on Structure Therapeutics in a research note on Thursday, March 26th. They issued a “peer perform” rating for the company. Wall Street Zen cut Structure Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Canaccord Genuity Group began coverage on Structure Therapeutics in a research note on Monday, April 27th. They issued a “buy” rating and a $101.00 price target for the company. Finally, HC Wainwright lowered their price target on Structure Therapeutics from $114.00 to $100.00 and set a “buy” rating for the company in a research note on Monday, March 16th.

Institutional Trading of Structure Therapeutics

A number of large investors have recently bought and sold shares of GPCR. Sterling Capital Management LLC bought a new stake in Structure Therapeutics during the 1st quarter worth approximately $28,000. State of Wyoming bought a new stake in Structure Therapeutics during the 2nd quarter worth approximately $28,000. EverSource Wealth Advisors LLC increased its stake in Structure Therapeutics by 530.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after purchasing an additional 901 shares in the last quarter. CWM LLC increased its stake in Structure Therapeutics by 35.2% during the 4th quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after purchasing an additional 125 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd increased its stake in Structure Therapeutics by 39.1% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock worth $114,000 after purchasing an additional 1,146 shares in the last quarter. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Price Performance

Shares of GPCR stock opened at $39.34 on Friday. The stock has a market cap of $2.80 billion, a PE ratio of -45.22 and a beta of -1.31. The stock has a 50-day moving average of $45.26 and a 200-day moving average of $56.87. Structure Therapeutics has a one year low of $15.80 and a one year high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04. As a group, research analysts anticipate that Structure Therapeutics will post -1.29 earnings per share for the current year.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.